Precision radiation may tame prostate cancer with fewer side effects

NCT ID NCT05616650

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 6 times

Summary

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole prostate. Participants will receive a special imaging tracer to help target the radiation precisely, and will be followed for two years with scans and a final biopsy to check if the cancer is gone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiation therapy (SBRT) and a single dose of 18F-DCFPyL (a radioactive tracer for imaging)
What this could lead to
If successful, this could offer a less invasive treatment option for early-stage prostate cancer with fewer side effects than whole-gland surgery or radiation.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to all patients. The treatment may not fully eliminate the cancer, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.